With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) causes almost as much weight loss as ...
Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes. This Comment highlights emerging evidence and ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Pharmacological therapies with incretin-based ‘multi-agonists’ are rapidly advancing the therapeutic landscape for obesity. The loss of skeletal muscle mass with these potent weight-loss agents is ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat obesity. Iuliia Burmistrova/Getty Images GLP-1 drugs have helped people successfully achieve and ...
New studies show that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) cause almost as much weight loss as gastric surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results